RNA-seq of nine canine prostate cancer cell lines reveals diverse therapeutic target signatures
Cancer Cell International volume 22, Article number: 54 (2022)
Canine prostate adenocarcinoma (PAC) and transitional cell carcinoma (TCC) are typically characterized by metastasis and chemoresistance. Cell lines are important model systems for developing new therapeutic strategies. However, as they adapt to culturing conditions and undergo clonal selection, they can diverge from the tissue from which they were originally derived. Therefore, a comprehensive characterization of cell lines and their original tissues is paramount.
This study compared the transcriptomes of nine canine cell lines derived from PAC, PAC metastasis and TCC to their respective original primary tumor or metastasis tissues. Special interests were laid on cell culture-related differences, epithelial to mesenchymal transition (EMT), the prostate and bladder cancer pathways, therapeutic targets in the PI3K-AKT signaling pathway and genes correlated with chemoresistance towards doxorubicin and carboplatin.
Independent analyses for PAC, PAC metastasis and TCC revealed 1743, 3941 and 463 genes, respectively, differentially expressed in the cell lines relative to their original tissues (DEGs). While genes associated with tumor microenvironment were mostly downregulated in the cell lines, patient-specific EMT features were conserved. Furthermore, examination of the prostate and bladder cancer pathways revealed extensive concordance between cell lines and tissues. Interestingly, all cell lines preserved downstream PI3K-AKT signaling, but each featured a unique therapeutic target signature. Additionally, resistance towards doxorubicin was associated with G2/M cell cycle transition and cell membrane biosynthesis, while carboplatin resistance correlated with histone, m- and tRNA processing.
Comparative whole-transcriptome profiling of cell lines and their original tissues identifies models with conserved therapeutic target expression. Moreover, it is useful for selecting suitable negative controls, i.e., cell lines lacking therapeutic target expression, increasing the transfer efficiency from in vitro to primary neoplasias for new therapeutic protocols. In summary, the dataset presented here constitutes a rich resource for canine prostate and bladder cancer research.
Prostate cancer in dogs can be classified into two histopathological groups: prostate adenocarcinoma (PAC) and transitional cell carcinoma (TCC) . Both are typically characterized by metastasis, local invasiveness, androgen-independence and chemoresistance [2, 3], which is why they have been proposed as models for human metastatic castration-resistant prostate cancer (MCRPC) and invasive bladder cancer [4, 5]. Unlike in men, canine prostate cancer is rarely diagnosed [6, 7], making tumor cell lines an indispensable in vitro model system and a vital tool in preclinical research [8, 9]. Notwithstanding their utility, results generated with cell lines are not unconditionally transferable to in vivo conditions. Indeed, through selection by multiple passaging, cell lines adapt to culturing conditions, resulting in differences in gene copy numbers, gene expression and protein synthesis between the cell lines and their original tumor tissues [10,11,12,13]. Thus, the suitability of a given cell line as model for a specific feature should be verified before initiating a clinical study. Applications for cell lines as in vitro models are versatile, including research on metastasis, targeted therapy and chemoresistance.
Metastasis involves a complex series of events. Among them, the epithelial-to-mesenchymal transition (EMT) plays a critical role in canine prostate cancer , since it promotes invasive growth and enables cell mobility and migration . EMT is also associated with enhanced chemoresistance . Evidently, to be of predictive value, the extent of EMT in cell lines should be comparable to that of the original tumor.
Chemotherapy can follow tumor type or patient-specific approaches [17,18,19]. Patient-specific therapy aims at targets, which are genes overexpressed by the tumor. Especially receptor tyrosine kinases (RTK) such as those involved in the PI3K-AKT signaling pathway are frequently targeted [20, 21]. Toceranib and masitinib are examples of RTK inhibitors that have been approved for the treatment of mast cell tumors in dogs [18, 20]. A stable expression of the therapeutic target and its downstream molecules in the utilized cell line is essential for conducting a preclinical study [22,23,24]. Consequently, genomic and transcriptomic profiling of cell lines in direct comparison to their respective original tumor tissues, as performed in the present study, are highly recommended [11, 13]. Tumor type-specific chemotherapy, on the other hand, relies on agents which are effective in the majority of cases in a heterogenous population of patients. Taking into account the enormous intra- and intertumoral heterogeneity of canine prostate cancer in dogs and men [1, 25, 26], chemosensitivity tests conducted on a panel of cell lines are of more practical use than those involving single cell lines . Recognizing this, the United States National Cancer Institute launched a screen of a panel of 60 human tumor cell lines more than 20 years ago; the screen is known as NCI-60 and is still active [27, 28]. For canine TCC, Dhawan et al. and Rathore et al. established a panel of well-characterized K9TCC cell lines [11, 29, 30]. Furthermore, a number of canine PAC cell lines have been profiled for different features as well [2, 31,32,33,34,35,36,37].
The present study aims to contribute to the existing knowledge of prostate cancer with the comprehensive transcriptomic characterization of a panel of four PAC, two PAC metastasis and three TCC cell lines and their original tumor tissues. Basic features of this sample set have been reported previously, including medical patient data, histopathology, doubling time, growth behavior, immunophenotype and chemosensitivity towards doxorubicin, carboplatin and meloxicam . Continuing from that point, the cell lines are herein investigated in direct comparison to their original tumor tissue using whole-transcriptome sequencing (Fig. 1). Whole-transcriptome sequencing is a high-throughput technology that is already used in veterinary and comparative oncology [38, 39]. It provides an overview of the complete gene expression landscape and enables detailed single gene expression analyses of therapeutically relevant targets [10, 21, 40, 41]. Specifically, the comparative characterization of the transcriptome of cell lines and their original tumor tissues as performed here has been proved a powerful approach to identify similarities and discrepancies between them . Alas, for many established cell lines, the original tumor tissue is not available or its quality is unsuitable for RNA sequencing and therefore, transcriptome level comparisons are rare . Comparing cell lines to the original tumor tissue in a whole-transcriptome sequencing approach, this study revealed conserved patient-specific characteristics, EMT-properties and downstream PI3K-AKT signaling, along with unique therapeutic target signatures and cell-culture-related adaptations. Together, these data provide suggestions as to which cell line might be the most suitable in vitro model to assess a specific therapeutic approach targeting canine metastatic prostate cancer.
Materials and methods
Ethical statement, tissue samples and cell lines
Tissue samples and one fine needle-aspiration biopsy of suspected prostate or bladder carcinomas were collected from ten patient dogs at the Small Animal Clinic, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany between 2003 and 2015 with the consent of the patients’ owners (Table 1). From one PAC patient (P4) and one TCC patient (P6), additional tissue samples of lymph node metastases were collected.
Each tissue sample was subsequently divided into three parts: The first part (“original tissue”) was fresh frozen in liquid nitrogen and stored at −80 °C until RNA isolation. The second part was histopathologically classified into PAC or TCC by a certified and experienced pathologist. Modified Gleason scores were between 8 and 10; metastasis confirmed in nearly all cases . Cell lines were established from the third part from four PAC patients, two additional lymph node metastases of a PAC patient (P4), and three TCC tissues . Cell lines were established as previously described (Table 1) . Culturing conditions were Medium 199 (Life Technologies GmbH, Darmstadt, Germany) containing 10% fetal calf serum (FBS Superior, Biochrom GmbH, Berlin, Germany), 200 IU/ml penicillin and 200 mg/ml streptomycin (Biochrom GmbH) at 37 °C in humidified air.
Each cell line was seeded in T25 flasks in triplicate beyond passage 60. At 70–80% confluency, cells were detached with TrypLE™Express (Life Technologies GmbH, Darmstadt, Germany), pelleted, fresh frozen in liquid nitrogen and stored at −80 °C until further use.
In accordance with German national legislation, this study does not require ethical approval, as all tissue samples were collected from: (1) a dog that was euthanized due to poor prognosis; or (2) a bladder cancer that was surgically removed as part of treatment; or (3) leftover material from a diagnostic fine needle aspiration biopsy.
Isolation of total RNA, library preparation and sequencing
RNA from cell pellets was isolated using the RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany), in accordance with the manufacturer’s protocols. For tissue samples, the AllPrep DNA/RNA/miRNA Universal Kit (Qiagen GmbH) was utilized as previously described . RNA was quantified photometrically on a take3 plate in a Synergy2 plate reader (BioTek Instruments GmbH, Bad Friedrichshall, Germany). Samples with RNA integrity numbers ≥ 5.2 measured with RNA 6000 Nano LabChip on an Agilent Bioanalyzer 2100 (Agilent Technologies Inc., Santa Clara, CA, USA) were further processed for library preparation using the NEBNext Ultra RNA preparation kit (New England Biolabs Inc., Ipswich, MA, USA). Tissue sample P4.1 was excluded due to low RNA integrity numbers in three independent trials of RNA-isolation. Single read sequencing was conducted on an Illumina NextSeq500 platform (Illumina Inc., San Diego, CA, USA) with a read length of 75 bp. For cell line Adcarc1258 and tissue samples P1 and P3, sequencing data of previously published experiments were used (Gene Expression Omnibus database accession identifier  GSE122916, samples PT-1 for P1 and PT-6 for P3). For cell line Adcarc1258, sequencing data of triplicates that served as solvent control (0.15% V/V DMSO) were used from a previous study (GSE162832) .
RNA-seq data preprocessing
Sequencing reads were trimmed and filtered using trimmomatic (v0.36, ) with parameters “-phred33, HEADCROP:11 LEADING:20 TRAILING:20 AVGQUAL:20 MINLEN:25”. Reads were mapped to the dog reference genome (Ensembl CanFam 3.1)  and corresponding gene model annotation (v94) using STAR (v2.5.3, ) with parameters: “–sjdbOverhang 100 –outSAMtype BAM SortedByCoordinate –quantMode TranscriptomeSAM GeneCounts”. RSEM (v.1.3.0, ) was used to quantify gene expression with parameters “–bam –no-bam-output”. Finally, for each library, read counts derived from multiple lanes were added together.
Differential expression analysis
Differential expression analysis was conducted with the DESeq2 R package . Only protein-coding genes were considered for the analysis. Read counts from technical triplicates were pooled before the analysis. Differential expression analysis was performed separately for each histopathological classification (PAC, PAC metastasis and TCC), using only samples for which both the original tissue and a cell line were available (Fig. 1). Expression was compared between original tissues and cell lines. The PAC and TCC samples originated from three (P1, P2 and P3) and two (P6 and P7) patients, respectively. The design formula used for the corresponding differential expression analyses controlled for patient effects (“design = ~ Patient + Type”, where “Patient” stands for the patient identifier and “Type” for the sample type, i.e., “original tissue” or “cell line”). The two PAC metastasis samples were derived from the same patient (P4); in this case, the design formula controlled for the biological replicate. Genes that (i) had an adjusted P-value smaller than or equal to 0.01; (ii) exhibited a fold-change greater than or equal to 2; and (iii) featured ten or more read counts in all original tissue samples or in all cell lines considered in the specific differential expression analysis were regarded as differentially expressed gene (DEG).
Expression values were obtained by applying the regularized logarithm transformation implemented in the rlog() function of the DESeq2 R package  to the raw read counts; no experimental design (“design = ~ 1”) was used for this purpose.
Visualization of gene expression profiles
Gene expression profiles (z-scores of the regularized-logarithm transformation) were visualized as heatmaps with the pheatmap() function from the homonymous R package . Clustering of genes was performed based on the Euclidean distance, using the complete linkage algorithm.
Examination of the specific invasive potential of each cell line
An invasion assay was performed to study EMT and metastatic potential of the nine cell lines. Thereby, cells which were allowed to migrate through an artificial basement membrane, attracted by a serum-containing medium, were quantified. In preparation, cell culture inserts with 8 µm pores in transparent PET membranes (Falcon ®, Corning Inc., Corning, NY, USA) were placed into 12 well plates and coated over night with 200 µg/ml basement membrane extract (Cultrex ®, Bio-Techne Corp., Minneapolis, MN, USA) in serum-free Medium 199 (Life Technologies GmbH). Additionally, the cells were starved overnight in serum-free medium. The next day, the starved cells were seeded with a density of 2.5 × 105 cells per insert in serum-free medium. The lower chambers of the wells were filled in duplicates with medium containing 10% serum as attractant, or with serum-free medium as controls. After 48 h of incubation, non-invasive cells were removed from the upper chamber with moistured cotton swabs and two washing steps with PBS. The remaining invasive cells were fixed in 10% formalin for 10 min and permeabilized by methanol for 20 min, both followed by washing twice in PBS. Subsequently, the cells were stained for 2 min with 1% crystal violet, washed three times and allowed to dry. Pictures of three representative areas on each membrane were taken with a DMI600 B microscope (Leica Microsystems, Wetzlar, Germany) in 100× magnification using the LAS AF 2.6.0 software. Finally, the area covered by invasive cells was quantified using Image J 2.0.0. The experiment was conducted three times independently. Means were compared by univariate ANOVA followed by a Ryan-Einot-Gabriel-Welsch post-hoc test using SAS Enterprise Guide® 7.15.
Functional analysis of DEGs was performed with DAVID (Database for annotation, visualization and integrated discovery tool) [53, 54], based on Gene Ontology Biological Processes (“GOTERM_BP_DIRECT”), Gene Ontology Cellular Component (“GOTERM_CC_DIRECT”) and a false discovery rate (FDR) of less than 5% as level of significance. The set of all 19,574 protein-coding genes in the dog genome was used as background. Retrieved enriched biological processes (GO_BP terms) were further categorized using REVIGO (reduce + visualize gene ontology) .
For PAC, PAC metastasis and TCC, a gene was considered expressed if it showed a minimum of ten reads in each cell line sample and/or each tissue sample.
Visualization of relevant pathways
The fold-changes of the DEGs in the Kyoto Encyclopedia of Genes and Genomes (KEGG) [56,57,58] prostate cancer pathway (cfa05215), bladder cancer pathway (cfa05219), and PI3K-Akt signaling pathway (cfa04151) were visualized with the Pathview web tool . The analysis was performed using Ensembl gene IDs. When one box represented multiple genes, the mean log2 foldchange was displayed.
Examination of specific targets at protein level by Western blot
All nine cell lines were washed three times with ice cold PBS and detached by scraping in RIPA buffer containing cOmpleteTM Mini Protease Inhibitor Cocktail (Roche GmbH, Mannheim, Germany). After cell lysis by ultrasound (Bandelin, Berlin, Germany), protein concentrations were determined by Bradford Assay (Bio-Rad Laboratories GmbH, Feldkirchen, Germany). Next, 30 µg cell lysate per well was separated by electrophoresis in Criterion™ TGX™ gels and blotted onto PVDF membranes using the Trans-Blot Turbo Transfer System (Bio-Rad Laboratories GmbH). The membranes were blocked in Odyssey blocking buffer (LI-COR Biosciences GmbH, Bad Homburg, Germany) diluted 1:3 in PBST for one hour at room temperature. Afterwards, the membranes were incubated with primary antibodies against PI3K-p110α (#4249, 1:1000), PI3K-p85 (#4292, 1:1000), Akt (#9272, 1:1000) and β-Actin (#4970, 1:5000) (all Cell Signaling Inc., Danvers, MA, USA) diluted in 1:5 blocking buffer in PBST at 4 °C overnight. The next day, the membranes were washed again, followed by incubation with fluorescence-labeled secondary antibodies (IRDye 800CW goat anti rabbit, LI-COR Biosciences GmbH) for one hour at room temperature. After three further washing steps, fluorescence signals were detected by a LI-COR Imager with Image Studio Lite software (LI-COR Biosciences GmbH). The Western blot analysis was repeated three times with subsequent passages. Protein lysates of the lymphoma cell lines GL-1 (canine), NALM-6 and SEM (both human) served as positive controls.
Human orthologs to canine genes
Human orthologs of canine genes were identified using the table of orthologous genes retrieved from Ensembl BioMart  on November 28, 2018. Specifically, canine Ensembl Gene IDs were used to obtain human Ensembl Gene IDs. Only genes with an orthology confidence score of 1 were considered orthologs. Among 19,574 Ensembl Gene IDs of canine protein-coding genes, 16,065 had an ortholog; in turn, the orthologs involved a total of 15,436 human Ensembl Gene IDs.
Identification of genes correlated with chemoresistance
Half maximal inhibitory concentrations of doxorubicin and carboplatin for all nine analyzed cell lines measured in metabolic activity and cell count in a previous study  were correlated with log2 transformed read counts of the present dataset. The ProGENI correlation  was guided by a network obtained from the STRING database for the species canis lupus . To match the gene expression data with the network information from SRTRING, Ensembl gene IDs were converted to Ensembl protein IDs by the bioDBnet conversion web tool  prior to analysis.
Furthermore, the top 300 genes ranked by ProGENI for doxorubicin or carboplatin resistance based on either metabolic activity or cell count were subjected to functional analysis with DAVID [53, 54]. Human orthologs of the identified top 300 genes were used, as up to now, the description of biological processes is described in much more detail for humans than for dogs. The complete set of 15,436 human orthologs of all 19,574 protein-coding genes in the dog genome was used as background. The level of significance was set to a false discovery rate (FDR) of less than 5%.
PAC and TCC cell lines conserved characteristics of their original tumor tissue despite large culture-induced gene expression changes
This study characterized seven cell lines of canine urinary tract cancer in direct comparison to their original tumor tissues. Previous histopathological examination  of the same samples had classified three of the tumor samples as PAC, two as PAC metastasis and two as TCC (Table 1). Principal component analysis (PCA) of the transcriptomic profiles of all samples clearly distinguished between cell lines and tissue samples (Fig. 2). Specifically, principal component (PC) 1 explained 49.5% of the variance in the data and separated cell lines from tissue samples; PC2 explained 11.63% of the variance in the data and mainly differentiated between two groups of original tissue samples: PAC, including PAC metastasis, and TCC (Fig. 2A). Based on PC2, the cell lines Adcarc1258 and TCC1509 were relatively far apart from other cell lines corresponding to the same histopathological classification. PC3 explained 6.25% of the variance in the data (Fig. 2B). PC3 distinguished between different patients. Note that for completeness, this analysis also included two cell lines without available tissues (one PAC and one TCC) and four tissue samples from which no cell line had been derived (three TCC and one TCC metastasis).
Immune response, cell adhesion and angiogenesis were commonly downregulated in PAC and TCC cell lines
Separate analyses for PAC, PAC metastasis, and TCC revealed 1743, 3941 and 463 DEGs, respectively, between the cell lines and their original tumor tissues when controlling for patient-specific effects (Methods). Independently of the histological classification of the samples, biological processes (GO_BP terms) enriched among the identified DEGs were associated with immune response, cell adhesion and angiogenesis/endodermal cell differentiation (Additional file 1). In addition, the DEGs in PAC samples were enriched in genes related to collagen fibril organization, calcium ion transport, lipoprotein metabolism and negative regulation of viral genome replication. Most of the DEGs (98%, 68% and 94%, respectively) were downregulated in the cell lines relative to the original tissue samples (Fig. 3). The majority of DEGs (2445; 62%) in the PAC metastasis samples were not differentially expressed in the PAC or TCC samples. In contrast, only 287 (17%) and 57 (12%) of the DEGs in the PAC and TCC samples were exclusive to PAC and TCC, respectively. A total of 310 DEGs were shared among all three histopathological classifications. The majority of DEGs, specifically 1300 (75%) in PAC, 1599 (41%) in PAC metastasis and 344 (74%) in TCC, featured large log2 fold-changes, greater than 5 or smaller than −5.
Cell lines preserved the epithelial or mesenchymal character of their original tumors
To validate the gene expression data and assess if the cell lines conserve the epithelial or mesenchymal character of their original tissue, an analysis of thirteen genes that had been previously investigated by immunohistochemistry or immunocytochemistry  was carried out. With the exception of PAC metastasis (Fig. 4B), most of these genes were not differentially expressed. In the PAC metastasis cell lines, the cytokeratins 7, 8, 14 and 18 were upregulated, while CNN1 was downregulated (Fig. 4B). In contrast, in the PAC group (Fig. 4A), cell line Adcarc1258, its tumor tissue P1 and the tumor P2 were noticeable due to their relatively low expression of the epithelial cytokeratin genes, CDH1 and UPK3A. Additionally, Adcarc1258 showed a relatively high expression of the mesenchymal marker VIM in trend, while the other PAC cell lines and tissue P3 behaved in the opposite manner. Similarly to Adcarc1258, the TCC cell line TCC1509 and the corresponding lymph node tissue Ln6.2 of the same patient had a remarkably high expression of the mesenchymal marker VIM (Fig. 4C). In general, TCC1509 appeared to be more similar to the metastasis tissue Ln6.2 than to its original tumor tissue (P6.1, Fig. 4C). Another remarkable observation among TCC samples was the fact that TCC1506 showed a relatively low expression of cytokeratins 8 and 18 (Fig. 4C).
While TCC cell lines conserved basal and luminal characteristics of the original tumor, both were downregulated in PAC metastasis cell lines, and basal features were downregulated in PAC cell lines
In a previous analysis, Dhawan et al. were able to classify their canine TCC tissue samples into a luminal and a basal subtype based on their gene expression profile . Thus, they compiled two gene lists characteristic for basal and luminal subtypes of canine and human bladder cancer . Similarly, human prostate cancer can be segregated into luminal and basal . When analyzing the list of 35 genes associated with basal subtypes in the dataset of the present study, 11, 22 and two genes were differentially expressed in PAC, PAC metastasis and TCC, respectively (Fig. 5). Cell lines and tissue samples generally showed different gene expression profiles (Fig. 5).
With the exception of the PAC metastasis samples (Fig. 6B), most of the 29 genes associated with luminal subtypes of canine and human bladder cancer  were not differentially expressed. Regarding the extent of luminal characteristics, the individual patients differed. For example, the PAC cell line Adcarc1258 and its corresponding tumor tissue P1 showed generally low expression for these genes (Figs. 5 and 6). The same phenomenon was observed in the TCC group for cell line TCC1509 and the respective lymph node metastasis tissue Ln6.2 (Fig. 6C). Consistently, compared to the respective tissues, both PAC metastasis cell lines showed a less luminal character (Fig. 6B).
Cell lines with low epithelial and luminal marker gene expression were highly invasive
An invasion assay was conducted to verify the mesenchymal transition suggested by the transcriptomic data. Invasive potential was measured as the area of the artificial basement membrane covered by invasive cells (Materials and Methods). Consistent with their high expression of the mesenchymal marker VIM and low expression of epithelial and luminal markers (Figs. 4 and 6), TCC1509 and Adcarc1258 exhibited the highest invasive potential among all analyzed cell lines (Fig. 7). Also TCC1506, which was notable for its low expression of cytokeratins 8 and 18, exhibited a highly invasive character. However, the total number of invaded cells in TCC1509 and Adcarc1258 is likely to be higher than in TCC1506 due to their relatively small cell size (Fig. 7B–D). The metastasis-derived cell lines, in which epithelial cytokeratin genes were upregulated (Fig. 4), were among the least invasive cell lines.
Cell lines conserved prostate and bladder cancer pathway gene expression, while certain prostate-specific genes were not expressed or downregulated
To further verify whether the cell lines reflect the tumor of origin, special focus was laid on the prostate and bladder cancer pathway genes. Of 97 genes listed in the KEGG [56,57,58] prostate cancer pathway (cfa05215) and 41 in the bladder cancer pathway (cfa05219), 89 and 39, respectively, were expressed at non-negligible levels (Methods) in the overall sample set. Among those, 14 genes in the prostate cancer pathway were differentially expressed in PAC samples and 35 in PAC metastasis samples (Fig. 8A). The differential expression within the prostate cancer pathway in PAC cell lines was mostly focused on MMP9 and the group of growth factors and their receptors (GFR), also known as RTK. DEGs in the metastasis cell lines were spread over the entire prostate cancer pathway, including the axes of carcinogenesis, RTKs and downstream molecules, and the hormonal axis (Fig. 8A, Table 2). Besides the pathway genes, hormonal receptors and other genes are of diagnostic and prognostic value in human and canine prostate cancer and were therefore of special interest in the present dataset (Table 2). Among these, ESR1, PGR and AMACR were not differentially expressed. In contrast, the androgen receptor, KLK2, NKX3-1 and ESR2 were not expressed and the prostate-specific markers ACPP, FOLH1, PSCA and GSTP1 were downregulated in the PAC and PAC metastasis cell lines.
Only three genes in the bladder cancer pathway were differentially expressed (in particular, they were downregulated) in TCC samples, including the urothelial marker UPK3A (Fig. 8B). In general, irrespective of the histopathological classification, the DEGs were not enriched in genes of any of these pathways.
PAC, PAC metastasis and TCC cell lines conserved the expression of certain therapeutic targets, as well as the PI3K-AKT signaling cascade
The PI3K-AKT signaling pathway (cfa04151) is an important regulator of the cell cycle and the focus of numerous therapeutic approaches [20, 21, 68]. Consequently, verifying that the genes involved in this pathway are expressed at similarly levels in the cell lines that are being considered as model systems relative to their original tissues is pivotal for preclinical studies. Of the 370 genes in the PI3K-AKT signaling pathway, 77, 124 and 29 were differentially expressed in PAC, PAC metastasis and TCC cell lines, respectively (Fig. 9). Irrespective of the histopathological classification, all sets of DEGs were enriched in genes in this pathway, and like the majority of the DEGs, most of the DEGs in the PI3K-Akt signaling pathway were downregulated.
Interestingly, PI3K and AKT, the key players of the pathway, were not differentially expressed. Moreover, their expression profiles could also be validated at protein level by performing a Western blot (Fig. 9B). Thus, in agreement with the transcriptomic data, AKT produced strong bands, especially in Adcarc1511.1, which featured relatively high transcript levels of AKT. Analogously, the weaker bands observed for PI3Kα and PI3K-p85 were in correspondence with their lower transcript levels. In particular, the concordance between mRNA and protein level was the most apparent in TCC1509, which featured the highest expression of PIK3R1/PI3K-p85. In addition, only a few genes in the subsequent downstream signaling cascade were differentially expressed, almost exclusively in PAC metastasis. Upstream of PI3K and AKT, of the 24 RTKs—the activators of the pathway and frequently targeted genes—10, 13, and 5 were differentially expressed in PAC, PAC metastasis and TCC, respectively. Thus, the expression of KIT, the main target of Masitinib and Toceranib in canine oncology [18, 20], appeared to be lost in culture. Nevertheless, other RTKs like ERBB2 and EGFR were not differentially expressed. Other targets showed varying gene expression levels in the different cell lines (Fig. 10, Additional file 4). PTGS2, which encodes COX-2, was also expressed, and even upregulated in the cell lines.
Resistance towards doxorubicin was associated with G2/M cell cycle transition, cell membrane biosynthesis and tumor microenvironment, while carboplatin resistance correlated with histone, m- and tRNA processing, TGFB receptor signaling and phagocytosis
Currently, there are no explicit treatment recommendations for canine prostate cancer. Therefore, the chemosensitivity of all nine analyzed cell lines to doxorubicin and carboplatin in metabolic activity and cell counts was assessed in a previous study . In a next step, the chemosensitivity was herein correlated with the gene expression data, guided by known protein networks from the STRING database . The top 300 genes correlated with doxorubicin resistance regarding metabolic activity (Additional files 2 and Additional file 3) were associated with mitosis, especially G2/M cell cycle transition and processes during the M phase, tRNA processing, platelet degranulation and cell membrane biosynthesis. Genes correlating with doxorubicin resistance in cell count were associated with tumor microenvironment, including cell adhesion, extracellular matrix organization, collagen catabolism and the integrin-mediated signaling pathway.
Carboplatin resistance regarding metabolic activity correlated with genes associated with histone deacetylation, glucose transport, oligosaccharide biosynthesis, TGFB receptor signaling pathway, mRNA 3prime-end processing and tRNA splicing. The set of the top 300 genes correlated with carboplatin resistance in cell count was associated with small GTPase mediated signal transduction, which includes numerous member genes of the RAS family of oncogenes. Furthermore, this set of genes was associated with movement of cell or subcellular components, phagocytosis, cytosol and centriole.
Additionally, other well-known multi-resistance genes were examined in the dataset. Of the three genes ABCB1, ABCC1 and ABCG2, coding for the multi-drug transporters MDR1, MRP and BCRP, ABCB1 was upregulated in PAC metastasis and TCC, while ABCG2 was downregulated in PAC and PAC metastasis.
An important decision in the planning of in vitro studies in prostate and bladder cancer research is the choice of an appropriate model system. Furthermore, only a detailed understanding and characterization of these tumor entities and the applied model systems allow a reasonable interpretation of the obtained results. The optimal reference for characterizing a cell line is the original tissue from which it was initially derived. However, in most cases, such a sample is either not available or not suitable for RNA-seq, and thus, such studies are scarce . The sample set analyzed herein, consisting of canine cell lines derived from four PAC, two PAC metastases and three TCC and their original tumor tissues, provides a rare opportunity.
In general, the present study found that tumor-, subtype- and patient-specific features were conserved in the cell lines compared to their original tissue samples, while genes associated with immune response, cell adhesion and angiogenesis were downregulated. This is consistent with the results by Perry et al., who compared two human squamous cell carcinoma cell lines to their original tumor tissues . Importantly, regarding the tumor entity, only few deviations were found between cell lines and tissues regarding the prostate and bladder cancer pathways.
Similar to other whole-genome transcriptome studies in human PAC  and canine lymphoma , the current analysis identified a relatively large number of DEGs. In contrast to those studies in which tumor tissues and cell lines originated from different patients, the observations made here cannot be attributed to patient-specific features or different tumor stages. Instead, there are a few possible explanations for the massive down-regulation of genes detected in the present analysis. First, cell lines are cultured in the absence of an immune system and with unlimited access to oxygen and nutrients. Second, cell lines are frequently detached in order to be passaged. Accordingly, processes such as immunoevasion, collagen fibril organization, angiogenesis and cell adhesion become non-essential and are downregulated. Nevertheless, it is worth mentioning that downregulation does not necessarily imply loss of function. Indeed, human tumor cell lines can reactivate genes associated with extracellular matrix organization, angiogenesis and cell adhesion in three-dimensional cultures or in mouse xenografts [70,71,72]. Similarly, Adcarc1258 is able to form three-dimensional spheroids with a modified gene expression compared to adherent Adcarc1258 cells and induces tumors in immunodeficient mice [73, 74].
The amount of tumor microenvironment and the degree of heterogeneity of the tissue samples may have also contributed to the differences in the number of DEGs observed for each histopathological classification. Thus, while previously published histopathological images of metastasis tissues Ln4.2 and Ln4.3 show lymphoid and connective tissue in addition to the tumor cell population, TCC tissue B7 consists almost exclusively of tumor cells . Consistently, Ln4.2 and Ln4.3 were further apart from their respective cell lines on PC1, which distinguished between cell lines and tissue samples (Fig. 2), than B7 was from its own. A microdissection of the tissue samples  prior to RNA isolation and sequencing would help to focus this analysis on the changes the pure tumor cell population underwent in the culturing process. Together with tumor microenvironment, patient heterogeneity may have contributed additionally to the variance in the measured data.
Despite the abovementioned adaptations to culturing conditions, the cell lines preserved the luminal or basal tumor subtypes and the epithelial or mesenchymal characteristics of the tumor. Both findings are consistent with observations from gene expression analyses of human cancer cell lines of various tumor entities [40, 76]. Especially Adcarc1258 and TCC1509 showed a remarkable extent of mesenchymal features regarding the expression pattern of luminal, basal and claudin genes. In this respect, Adcarc1258 displayed similarities to its original tumor tissue and TCC1509 to the respective lymph node metastasis Ln6.2. Consistently, their morphology and growth behavior in cell culture is characterized by high cell mobility, cell protrusions, low adherence, the tendency to form spheroids , and highest invasive potential. With the exception of the intermediate cell line TCC1506, the other six cell lines were significantly less invasive and feature a more epithelial, cobblestone-like growth behavior . Chaffer et al. showed a similar relationship between EMT and invasive potential in vitro for human bladder cancer cell lines . However, contrary to the expectation, the cell lines with the highest metastatic potential in in vivo mouse models  featured epithelial characteristics in vitro. In order to establish distant colonies, metastatic tumor cells reverse EMT and revert to an epithelial phenotype . This epithelial-mesenchymal plasticity could explain the low invasive potential of the two metastasis cell lines. Although the phenotype and doubling times of both PAC metastasis cell lines Metadcarc1511.2 and Metadcarc1511.3 were completely different from the primary tumor cell line Adcarc1511.1 of the same patient , the similarity of all samples from this patient was striking (Fig. 2). In other words, differences in gene expression profiles between PAC tumors of different individuals were much greater than differences between primary tumor and metastasis. These three cell lines offer the rare opportunity to evaluate EMT or perform chemosensitivity tests in cell lines established from primary tumors and metastases of the same patient, preventing patient-specific differences from confounding the results.
The androgen receptor is the most important driver in human prostate cancer. Despite initial success of androgen-deprivation therapy, many men develop androgen-independent MCRPC, in which mutations or splice variants enable the tumor to continue to rely on androgen receptor signaling . Due to its androgen-independence, canine prostate cancer has been proposed as biological model for MCRPC . In contrast to MCRPC, and consistent with other reports [2, 3, 31, 34,35,36, 39, 80], in the present study the androgen receptor was found to be not expressed in canine prostate cancer tissues and cell lines. The divergent expression of hormonal receptors in human and canine prostate cancer [81,82,83,84] argues against the suitability of canine prostate cancer as a model for androgen receptor signaling in human MCRPC. Furthermore, because prostatic TCC is rare in men [1, 82], only canine PAC can be seen as model for MCRPC. Distinction between PAC and TCC, which is also important for therapeutic decisions , can be achieved on the basis of the expression of the urothelial marker UPK3A . Interestingly, the current analysis observed that UPK3A was downregulated in the analyzed TCC cell lines. Furthermore, and in contrast to other canine TCC cell lines , the UPK3A protein was not detectable by immunohistochemistry using an antibody with confirmed species immunoreactivity in any of the analyzed samples . A possible reason for this is the loss of UPK3A immunoreactivity in high grade TCC .
Although cell lines are common model systems for targeted chemotherapy, results obtained with cell lines are not always reproducible in clinical trials . The main explanation for this is that cell lines undergo clonal selection and therefore often no longer reflect the tumor’s specific target expression . The PI3K signaling pathway is of particular interest in canine prostate cancer  and chemotherapy in general [20, 21]. As an important result, the key players of the PI3K signaling pathway, PI3K and AKT, were not differentially expressed between cell lines and tissues (except for AKT1 and PIK3CD in PAC metastasis, log2 fold-changes 1.0 and −1.9). Furthermore, only few downstream genes were differentially expressed, almost exclusively in the PAC metastasis cell lines. Although the functionality of the corresponding proteins warrants further investigation, these findings indicate a good model suitability of the analyzed cell lines for the downstream PI3K signaling cascade. This observation is surprising given that numerous RTKs—direct activators of PI3K—were downregulated. In general, each cell line exhibited its own individual therapeutic marker signature. For instance, the RTK FGFR2 is targeted by erdafitinib, an inhibitor for the treatment of human metastatic bladder cancer . Although FGFR2 was generally downregulated in PAC cell lines, Adcarc0846 and Adcarc1511.1 appear to have similar FGFR2 expression levels relative to their original tissues. Thus, those two PAC-derived cell lines may still represent suitable model systems for an FGFR2-targeted approach. Furthermore, canine and human TCC tissues and cell lines have been found to overexpress the RTKs EGFR and ERBB2 [65, 89,90,91]. This overexpression is thought to be relevant for tumor progression, making EGFR a therapeutic target. A first study has shown promising effects of the EGFR and ERBB2 inhibitor lapatinib on canine TCC cell lines , while the EGFR inhibitor erlotinib reduced proliferation in a subset of human TCCs [93, 94]. EGFR and ERBB2 were not differentially expressed in the present sample set, suggesting that the characterized cell lines are suitable models for EGFR-targeted therapies. Furthermore, the tyrosine kinases and therapeutical targets EPHA2, MET, LYN and PDGFRA were expressed by specific cell lines at the same level compared to the average of the tissues. Claudins participate in the formation of tight junctions and are therefore essential for the maintenance of an epithelial structure. To promote EMT and metastasis, tight junctions are dismantled in favor of a more invasive, mesenchymal cell type [43, 95]. Therefore, claudins play an important role in tumor progression and are promising therapeutic targets [43, 96]. The present findings confirm the results of a previous study investigating these four claudins at RNA and protein level in Adcarc1258, Adcarc0846 and TCC0840 . Among PAC cell lines, Adcarc0846 had the highest expression of CLDN1, 3, 4 and 7 and the lowest invasive potential and is hence the most suitable for a claudin-targeted therapy approach. In contrast, Adcarc1258 was highly invasive, expressed all four claudin genes at the lowest level among all cell lines and could therefore be used as negative control.
Correlating molecular marker signatures with outcome or chemoresistance can help unravel resistance mechanisms and identify predictive markers  for personalized medicine [18, 98, 99]. ProGENI found a correlation between the G2/M transition of the mitotic cell and resistance to doxorubicin in the nine analyzed cell lines. Consistently, doxorubicin arrests the human PAC cell line DU145  in the G2/M transition and thereby induces apoptosis. Presumably, an altered G2/M transition might now explain the failure of doxorubicin to induce apoptosis in the particularly resistant Metadcarc1511.2 and Metadcarc1511.3 . Furthermore, doxorubicin resistance in cell count was herein associated with a modified phosphatidylserine and phosphoethanolamine biosynthesis. The authors of a study conducted on doxorubicin-resistant MCF7 cells  obtained similar results and discussed a less fluid cell membrane as one aspect of chemoresistance. However, it remains to be investigated whether the particular doxorubicin resistance of Metadcarc1511.2 and Metadcarc1511.3 is truly associated with these findings, or whether it is simply a patient-specific feature. Consistent with results of other research groups [102, 103], ProGENI correlated resistance towards platinum drugs with modifications in histone deacetylation. Following this approach, histone deacetylase inhibitors show anti-proliferative effects against canine PAC and TCC cell lines, and might be promising when combined with carboplatin [35, 86, 104]. Additionally, recent studies confirmed binding sites of cisplatin and doxorubicin to tRNA [105, 106]. This supports the observed association of tRNA splicing and the tRNA-intron endonuclease complex with carboplatin and doxorubicin resistance in the characterized nine cell lines. However, this analysis was limited by the relatively small sample size of nine canine cell lines. As next generation sequencing emerges in veterinary medicine, this analysis should be repeated with the transcriptomic and chemosensitivity data of more canine cell lines. Another interesting aspect might be to repeat this analysis, including cell lines selected for doxorubicin or carboplatin resistance.
Last but not least, this analysis is based on the transcriptome and only selected genes were verified on the protein level. Since translation is influenced by multiple regulatory mechanisms, mRNA levels are not unconditionally transferrable to protein levels . Additionally, protein functionality might be affected by mutations and alternative splicing, which was also not the subject of this analysis. Targeted chemotherapy and resistance mechanisms operate on the protein level. Thus, the targets of interest and their functionality warrant further investigation. Furthermore, since the cell lines were examined only at one time-point, this study is unable to make definitive statements concerning their gene expression stability. However, the present study characterized the cell lines beyond passage 60 and the largest changes in cell lines normally occur during the first 30 passages . Hence, a certain stability can be assumed.
In essence, compared to their original tumor tissues, the nine canine cell lines characterized in the present study conserved EMT gene expression programs and downstream PI3K-AKT signaling. Due to their individual therapeutic target signatures, they constitute a suitable panel to evaluate a large variety of inhibitors in vitro. Additionally, the panel includes cell lines derived from primary tumors and metastases of the same patient, which are interesting subjects for metastasis research.
Enabled by the rare availability of the tissue samples from which they were derived, this study assessed at the transcriptomic level nine canine PAC, PAC metastasis and TCC cell lines as in vitro models for targeted therapies in canine prostate cancer. Adaptation to culturing conditions and clonal selection resulted in the downregulation of genes associated with tumor microenvironment in the cell lines compared to their original tissues, while tumor- and patient-specific characteristics, as well as the extent of EMT, were mostly conserved. Most importantly, all nine cell lines featured unique therapeutic target expression signatures and preserved subsequent signaling cascades. In summary, this dataset constitutes a rich resource for choosing suitable in vitro models for testing future therapeutic approaches for canine prostate cancer.
Availability of data and materials
The datasets generated and/or analyzed during the current study are available in the Gene Expression Omnibus database, [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE190374].
Transitional cell carcinoma
Metastatic castration-resistant prostate cancer
Epithelial to mesenchymal transition
Receptor tyrosine kinases
University of Veterinary Medicine Hannover
Urinary tract (urinary bladder)
Metastasis of an adenocarcinoma
Spliced Transcripts Alignment to a Reference
Database for annotation, visualization and integrated discovery tool
False discovery rate
Reduce + visualize gene ontology
Kyoto Encyclopedia of Genes and Genomes
Prioritization of Genes Enhanced with Network Information
Search tool for recurring instances of neighboring genes
Growth factor receptor
Palmieri C, Foster RA, Grieco V, Fonseca-Alves CE, Wood GA, Culp WTN, et al. Histopathological terminology standards for the reporting of prostatic epithelial lesions in dogs. J Comp Pathol. 2019;171:30–7. https://doi.org/10.1016/j.jcpa.2019.07.005.
Azakami D, Nakahira R, Kato Y, Michishita M, Kobayashi M, Onozawa E, et al. The canine prostate cancer cell line CHP-1 shows over-expression of the co-chaperone small glutamine-rich tetratricopeptide repeat-containing protein α. Vet Comp Oncol. 2017;15:557–62. https://doi.org/10.1111/vco.12199.
Rivera-Calderón LG, Fonseca-Alves CE, Kobayashi PE, Carvalho M, Drigo SA, de Oliveira VR, et al. Alterations in PTEN, MDM2, TP53 and AR protein and gene expression are associated with canine prostate carcinogenesis. Res Vet Sci. 2016;106:56–61. https://doi.org/10.1016/j.rvsc.2016.03.008.
Fulkerson CM, Dhawan D, Ratliff TL, Hahn NM, Knapp DW. Naturally occurring canine invasive urinary bladder cancer: a complementary animal model to improve the success rate in human clinical trials of new cancer drugs. Int J Genomics. 2017. https://doi.org/10.1155/2017/6589529.
Fonseca-Alves CE, Vicente IST, Calazans SG, Laufer-Amorim R. Canine prostate cancer: would the dog be an important model for the study of new drugs? Am J Drug Discov Dev. 2013;3:220–4. https://doi.org/10.3923/ajdd.2013.220.224.
Krook L. a Statistical investigation of carcinoma in the dog. Acta Pathol Microbiol Scand. 1954. https://doi.org/10.1111/j.1699-0463.1954.tb00886.x.
Bell FW, Klausner JS, Hayden DW, Feeney DA, Johnston SD. Clinical and pathologic features of prostatic adenocarcinoma in sexually intact and castrated dogs: 31 cases (1970–1987). J Am Vet Med Assoc. 1991; 1623–30. http://www.ncbi.nlm.nih.gov/pubmed/1778750.
Cunningham D, You Z. In vitro and in vivo model systems used in prostate cancer research. J Biol Methods. 2015;2:1–28. https://doi.org/10.14440/jbm.2015.63.In.
Yamori T. Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. Cancer Chemother Pharmacol Suppl. 2003;52:S74–9. https://doi.org/10.1007/s00280-003-0649-1.
Ertel A, Verghese A, Byers SW, Ochs M, Tozeren A. Pathway-specific differences between tumor cell lines and normal and tumor tissue cells. Mol Cancer. 2006;5:55. https://doi.org/10.1186/1476-4598-5-55.
Shapiro SG, Knapp DW, Breen M. A cultured approach to canine urothelial carcinoma: molecular characterization of five cell lines. Canine Genet Epidemiol. 2015;2:15. https://doi.org/10.1186/s40575-015-0028-3.
Hammer S, Becker A, Rateitschak K, Mohr A, Lüder Ripoli F, Hennecke S, et al. Longitudinal claudin gene expression analyses in canine mammary tissues and thereof derived primary cultures and cell lines. Int J Mol Sci. 2016;17:1655. https://doi.org/10.3390/ijms17101655.
Laufer-Amorim R, Fonseca-Alves C, Villacis R, Linde S, Carvalho M, Larsen S, et al. Comprehensive genomic profiling of androgen-receptor-negative canine prostate cancer. Int J Mol Sci. 2019;20:1555. https://doi.org/10.3390/ijms20071555.
Fonseca-Alves CE, Kobayashi PE, Rivera-Calderon LG, Laufer-Amorim R. Evidence of epithelial-mesenchymal transition in canine prostate cancer metastasis. Res Vet Sci. 2015;100:176–81. https://doi.org/10.1016/j.rvsc.2015.03.001.
Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: a historical overview. Transl Oncol. 2020;13: 100773. https://doi.org/10.1016/J.TRANON.2020.100773.
Wade C, Kyprianou N. Profiling prostate cancer therapeutic resistance. Int J Mol Sci. 2018;19:904. https://doi.org/10.3390/ijms19030904.
Derleth CL, Yu EY. Targeted therapy in the treatment of castration-resistant prostate cancer. Oncol (United States). 2013;27:1–8.
Klopfleisch R. Personalised medicine in veterinary oncology: one to cure just one. Vet J. 2015;205:128–35. https://doi.org/10.1172/JCI76094.
Katogiritis A, Khanna C. Towards the delivery of precision veterinary cancer medicine. Vet Clin North Am Small Anim Pract. 2019;49:809–18. https://doi.org/10.1016/j.cvsm.2019.04.011.
Londhe P, Gutwillig M, London C. Targeted therapies in veterinary oncology. Vet Clin North Am Small Anim Pract. 2019;49:917–31. https://doi.org/10.1016/j.cvsm.2019.04.005.
Yadav SS, Li J, Lavery HJ, Yadav KK, Tewari AK. Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment. Urol Oncol Semin Orig Investig. 2015. https://doi.org/10.1016/j.urolonc.2015.02.009.
Barretina J, Caponigro G, Stransky N. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity. Nature. 2012;483:603–7. https://doi.org/10.1038/nature11003.The.
Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013;4:2126. https://doi.org/10.1038/ncomms3126.
Khaznadar SS, Khan M, Schmid E, Gebhart S, Becker ET, Krahn T, et al. EGFR overexpression is not common in patients with head and neck cancer. Cell lines are not representative for the clinical situation in this indication. Oncotarget. 2018;9:28965–75. https://doi.org/10.18632/oncotarget.25656.
Palmieri C, Lean FZ, Akter SH, Romussi S, Grieco V. A retrospective analysis of 111 canine prostatic samples: histopathological findings and classification. Res Vet Sci. 2014;97:568–73. https://doi.org/10.1016/j.rvsc.2014.11.006.
Packer JR, Maitland NJ. The molecular and cellular origin of human prostate cancer. Biochim Biophys Acta Mol Cell Res. 2016;1863:1238–60. https://doi.org/10.1016/J.BBAMCR.2016.02.016.
Gillet J-P, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. J Natl Cancer Inst. 2013;105:452–8. https://doi.org/10.1093/jnci/djt007.
Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6:813–23. https://doi.org/10.1038/nrc1951.
Dhawan D, Ramos-Vara JA, Stewart JC, Zheng R, Knapp DW. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer. Urol Oncol Semin Orig Investig. 2009;27:284–92. https://doi.org/10.1016/j.urolonc.2008.02.015.
Rathore K, Cekanova M. Animal model of naturally occurring bladder cancer: characterization of four new canine transitional cell carcinoma cell lines. BMC Cancer. 2014;14:465. https://doi.org/10.1186/1471-2407-14-465.
Eaton CL, Pierrepoint CG. Growth of a spontaneous canine prostatic adenocarcinoma in vivo and in vitro: isolation and characterization of a neoplastic prostatic epithelial cell line, CPA 1. Prostate. 1988;12:129–43.
Anidjar M, Scarlata E, Cury FL, Rocha J, Hamel L, Luz M, et al. Refining the orthotopic dog prostate cancer (DPC)-1 model to better bridge the gap between rodents and men. Prostate. 2012;72:752–61. https://doi.org/10.1002/pros.21479.
Winkler S, Murua Escobar H, Eberle N, Reimann-Berg N, Nolte I, Bullerdiek J. Establishment of a cell line derived from a canine prostate carcinoma with a highly rearranged karyotype. J Hered. 2005;96:782–5. https://doi.org/10.1093/jhered/esi085.
LeRoy BE, Thudi NK, Nadella MVP, Toribio RE, Tannehill-Gregg SH, Van Bokhoven A, et al. New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft. Prostate. 2006;66:1213–22. https://doi.org/10.1002/pros.20408.
Thudi NK, Shu ST, Martin CK, Lanigan LG, Nadella MVP, Van Bokhoven A, et al. Development of a brain metastatic canine prostate cancer cell line. Prostate. 2011;71:1251–63. https://doi.org/10.1002/pros.21341.
Simmons JK, Dirksen WP, Hildreth BE, Dorr C, Williams C, Thomas R, et al. Canine prostate cancer cell line (Probasco) produces osteoblastic metastases in vivo. Prostate. 2014;74:1251–65. https://doi.org/10.1002/pros.22838.
Packeiser E-M, Hewicker-Trautwein M, Thiemeyer H, Mohr A, Junginger J, Schille JT, et al. Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis. Nie D, editor. PLoS One. 2020; 15:e0230272. https://doi.org/10.1371/journal.pone.0230272
Pang LY, Argyle DJ. Veterinary oncology: biology, big data and precision medicine. Vet J. 2016;213:38–45. https://doi.org/10.1016/J.TVJL.2016.03.009.
Thiemeyer H, Taher L, Schille JT, Packeiser E, Harder LK, Hewicker-trautwein M, et al. An RNA-Seq-based framework for characterizing canine prostate cancer and prioritizing clinically relevant biomarker candidate genes. 2021; 1–19.
Klijn C, Durinck S, Stawiski EW, Haverty PM, Jiang Z, Liu H, et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol. 2014;33:306–12. https://doi.org/10.1038/nbt.3080.
Reis-Filho JS. Next-generation sequencing. Breast Cancer Res. 2009;11:S12. https://doi.org/10.1186/bcr2431.
Perry J, Ashford B, Singh Thind A, Gauthier M-E, Minaei E, Major G, et al. Comprehensive mutational and phenotypic characterization of new metastatic cutaneous squamous cell carcinoma cell lines reveal novel drug susceptibilities. Int J Mol Sci. 2020;2020:9536. https://doi.org/10.3390/ijms21249536.
Hammer SC, Nagel S, Junginger J, Hewicker-Trautwein M, Wagner S, Heisterkamp A, et al. Claudin-1, -3, -4 and -7 gene expression analyses in canine prostate carcinoma and mammary tissue derived cell lines. Neoplasma. 2016;63:231–8. https://doi.org/10.4149/208_150924N505.
Harting T, Stubbendorff M, Willenbrock S, Wagner S, Schadzek P, Ngezahayo A, et al. The effect of dichloroacetate in canine prostate adenocarcinomas and transitional cell carcinomas in vitro. Int J Oncol. 2016;49:2341–50. https://doi.org/10.3892/ijo.2016.3720.
Thiemeyer H, Taher L, Schille JT, Harder L, Hungerbuehler SO, Mischke R, et al. Suitability of ultrasound-guided fine-needle aspiration biopsy for transcriptome sequencing of the canine prostate. Sci Rep. 2019;9:13216. https://doi.org/10.1038/s41598-019-49271-1.
Schille JT, Nolte I, Beck J, Jilani D, Roolf C, Pews-Davtyan A, et al. PDA indolylmaleimides induce anti-tumor effects in prostate carcinoma cell lines through mitotic death. Front Vet Sci. 2021;7: 558135. https://doi.org/10.3389/fvets.2020.558135.
Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114–20. https://doi.org/10.1093/bioinformatics/btu170.
Cunningham F, Achuthan P, Akanni W, Allen J, Amode MR, Armean IM, et al. Ensembl 2019. Nucleic Acids Res. 2018;47:745–51. https://doi.org/10.1093/nar/gky1113.
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21. https://doi.org/10.1093/bioinformatics/bts635.
Li B, Dewey CN. RSEM: Accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinform. 2011. https://doi.org/10.1186/1471-2105-12-323.
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. https://doi.org/10.1186/s13059-014-0550-8.
Kolde R. CRAN—package pheatmap. Cran.R-Project.Org. 2019. https://cran.r-project.org/web/packages/pheatmap/index.html. Accessed 8 Nov 2020.
Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37:1–13. https://doi.org/10.1093/nar/gkn923.
Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57. https://doi.org/10.1038/nprot.2008.211.
Supek F, Bošnjak M, Škunca N, Šmuc T. REVIGO Summarizes and visualizes long lists of gene ontology terms. Gibas C, editor. PLoS One. 2011; 6:e21800. https://doi.org/10.1371/journal.pone.0021800.
Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49:D545–51. https://doi.org/10.1093/nar/gkaa970.
Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28:1947–51. https://doi.org/10.1002/pro.3715.
Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of genes and genomes. Nucleic Acids Res. 2000. https://doi.org/10.1093/nar/28.1.27.
Luo W, Pant G, Bhavnasi YK, Blanchard SG, Brouwer C. Pathview Web: user friendly pathway visualization and data integration. Nucleic Acids Res. 2017;45:W501–8. https://doi.org/10.1093/nar/gkx372.
Kinsella RJ, Kahari A, Haider S, Zamora J, Proctor G, Spudich G, et al. Ensembl BioMarts: a hub for data retrieval across taxonomic space. Database. 2011;201:bar030. https://doi.org/10.1093/database/bar030.
Emad A, Cairns J, Kalari KR, Wang L, Sinha S. Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance. Genome Biol. 2017;18:153. https://doi.org/10.1186/s13059-017-1282-3.
Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43:D447–52. https://doi.org/10.1093/nar/gku1003.
Mudunuri U, Che A, Yi M, Stephens RM, Bateman A. bioDBnet: the biological database network. Bioinforma Appl NOTE. 2009;25:555–6. https://doi.org/10.1093/bioinformatics/btn654.
Lex A, Gehlenborg N, Strobelt H, Vuillemot R, Pfister H. UpSet: visualization of intersecting sets. IEEE Trans Vis Comput Graph. 2014;20:1983–92. https://doi.org/10.1109/TVCG.2014.2346248.
Dhawan D, Paoloni M, Shukradas S, Choudhury DR, Craig BA, Ramos-Vara JA, et al. Comparative gene expression analyses identify luminal and basal subtypes of canine invasive urothelial carcinoma that mimic patterns in human invasive bladder cancer. PLoS ONE. 2015;10:1–15. https://doi.org/10.1371/journal.pone.0136688.
Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, et al. Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy. JAMA Oncol. 2017;3:1663–72. https://doi.org/10.1001/jamaoncol.2017.0751.
Kanehisa Lab. KEGG PATHWAY Database. https://www.genome.jp/kegg/pathway.html. Accessed 28 Nov 2020.
Kong W, Sender S, Perez SV, Sekora A, Ruetgen B, Junghanss C, et al. Pan- and isoform-specific inhibition of the bromodomain and extra-terminal proteins and evaluation of synergistic potential with entospletinib in canine lymphoma. Anticancer Res. 2020;40:3781–92. https://doi.org/10.21873/anticanres.14367.
Taher L, Beck J, Liu W, Roolf C, Soller JT, Rütgen BC, et al. Comparative high-resolution transcriptome sequencing of lymphoma cell lines and de novo lymphomas reveals cell-line-specific pathway dysregulation. Sci Rep. 2018;8:6279. https://doi.org/10.1038/s41598-018-23207-7.
Myungjin Lee J, Mhawech-Fauceglia P, Lee N, Cristina Parsanian L, Gail Lin Y, Andrew Gayther S, et al. A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab Investig. 2013;93:528–42. https://doi.org/10.1038/labinvest.2013.41.
Zschenker O, Streichert T, Hehlgans S, Cordes N. Genome-wide gene expression analysis in cancer cells reveals 3D growth to affect ECM and processes associated with cell adhesion but not DNA repair. Borgmann K, editor. PLoS One. 2012; 7:e34279. https://doi.org/10.1371/journal.pone.0034279
Creighton C, Kuick R, Misek DE, Rickman DS, Brichory FM, Rouillard JM, et al. Profiling of pathway-specific changes in gene expression following growth of human cancer cell lines transplanted into mice. Genome Biol. 2003;4:R46. https://doi.org/10.1186/gb-2003-4-7-r46.
Liu W, Moulay M, Willenbrock S, Roolf C, Junghanss C, Ngenazahayo A, et al. Comparative characterization of stem cell marker expression, metabolic activity and resistance to doxorubicin in adherent and spheroid cells derived from the canine prostate adenocarcinoma cell line CT1258. Anticancer Res. 2015;35:1917–27.
Fork MA, Murua Escobar H, Soller JT, Sterenczak KA, Willenbrock S, Winkler S, et al. Establishing an in vivo model of canine prostate carcinoma using the new cell line CT1258. BMC Cancer. 2008;8:240. https://doi.org/10.1186/1471-2407-8-240.
Shukla CJ, Pennington CJ, Riddick ACP, Sethia KK, Ball RY, Edwards DRW. Laser-capture microdissection in prostate cancer research: establishment and validation of a powerful tool for the assessment of tumour-stroma interactions. BJU Int. 2008;101:765–74. https://doi.org/10.1111/j.1464-410X.2007.07372.x.
Goodspeed A, Heiser LM, Gray JW, Costello JC. Tumor-derived cell lines as molecular models of cancer pharmacogenomics. Mol Cancer Res. 2016. https://doi.org/10.1158/1541-7786.MCR-15-0189.
Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res. 2006;66:11271–8. https://doi.org/10.1158/0008-5472.CAN-06-2044.
Garg M. Urothelial cancer stem cells and epithelial plasticity: current concepts and therapeutic implications in bladder cancer. Cancer Metastasis Rev. 2015. https://doi.org/10.1007/s10555-015-9589-6.
Coutinho I, Day TK, Tilley WD, Selth LA. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocr Relat Cancer. 2016;23:T179–97. https://doi.org/10.1530/ERC-16-0422.
Anidjar M, Villette J-M, Devauchelle P, Delisle F, Cotard JP, Billotey C, et al. In vivo model mimicking natural history of dog prostate cancer using DPC-1, a new canine prostate carcinoma cell line. Prostate. 2001;46:2–10. https://doi.org/10.1002/1097-0045(200101)46:1%3c2::AID-PROS1002%3e3.0.CO;2-5.
Kristiansen G. Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer. Mod Pathol. 2018. https://doi.org/10.1038/modpathol.2017.168.
Lai CL, Van Den Ham R, Van Leenders G, Van Der Lugt J, Mol JA, Teske E. Histopathological and immunohistochemical characterization of canine prostate cancer. Prostate. 2008;68:477–88. https://doi.org/10.1002/pros.20720.
Bell FW, Klausner JS, Hayden DW, Lund EM, Liebenstein BB, Feeney DA, et al. Evaluation of serum and seminal plasma markers in the diagnosis of canine prostatic disorders. J Vet Intern Med. 1995;9:149–53. https://doi.org/10.1111/j.1939-1676.1995.tb03288.x.
Leis-Filho AF, Fonseca-Alves CE. Anatomy, histology, and physiology of the canine prostate gland. Vet Anat Physiol. 2019. https://www.intechopen.com/books/veterinary-anatomy-and-physiology/anatomy-histology-and-physiology-of-the-canine-prostate-gland. https://doi.org/10.5772/intechopen.81410.
Lai CL, Van Den Ham R, Van Leenders G, Van Der Lugt J, Teske E. Comparative characterization of the canine normal prostate in intact and castrated animals. Prostate. 2008;68:498–507. https://doi.org/10.1002/pros.20721.
Eto S, Saeki K, Yoshitake R, Yoshimoto S, Shinada M, Ikeda N, et al. Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells. PLoS One. 2019. https://doi.org/10.1371/journal.pone.0218382.
Sledge DG, Patrick DJ, Fitzgerald SD, Xie Y, Kiupel M. Differences in expression of uroplakin III, cytokeratin 7, and cyclooxygenase-2 in canine proliferative urothelial lesions of the urinary bladder. Vet Pathol. 2015;52:74–82. https://doi.org/10.1177/0300985814522819.
Montazeri K, Bellmunt J. Erdafitinib for the treatment of metastatic bladder cancer. Expert Rev Clin Pharmacol. 2020;13:1–6. https://doi.org/10.1080/17512433.2020.1702025.
Hanazono K, Fukumoto S, Kawamura Y, Endo Y, Kadosawa T, Iwano H, et al. Epidermal growth factor receptor expression in canine transitional cell carcinoma. J Vet Med Sci. 2015;77:1–6. https://doi.org/10.1292/jvms.14-0032.
Li W, Wang Y, Tan S, Rao Q, Zhu T, Huang G, et al. Overexpression of epidermal growth factor receptor (EGFR) and HER-2 in bladder carcinoma and its association with patients’ clinical features. Med Sci Monit. 2018;24:7178–85. https://doi.org/10.12659/MSM.911640.
Maeda S, Tomiyasu H, Tsuboi M, Inoue A, Ishihara G, Uchikai T, et al. Comprehensive gene expression analysis of canine invasive urothelial bladder carcinoma by RNA-Seq. BMC Cancer. 2018;18:1–11. https://doi.org/10.1186/s12885-018-4409-3.
Sakai K, Maeda S, Saeki K, Nakagawa T, Murakami M, Endo Y, et al. Anti-tumour effect of lapatinib in canine transitional cell carcinoma cell lines. Vet Comp Oncol. 2018;16:642–9. https://doi.org/10.1111/vco.12434.
Pruthi RS, Nielsen M, Heathcote S, Wallen EM, Rathmell WK, Godley P, et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int. 2010;106:349–54. https://doi.org/10.1111/j.1464-410X.2009.09101.x.
Goodspeed A, Jean A, Theodorescu D, Costello JC. A gene expression signature predicts bladder cancer cell line sensitivity to EGFR inhibition. Bl Cancer. 2018;4:269–82. https://doi.org/10.3233/BLC-170161.
Tabariès S, Siegel PM. The role of claudins in cancer metastasis. Oncogene. 2017;36:1176–90. https://doi.org/10.1038/ONC.2016.289.
Kwon MJ. Emerging roles of claudins in human cancer. Int J Mol Sci. 2013. https://doi.org/10.3390/ijms140918148.
Peters D, Freund J, Ochs RL. Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer Ther. 2005;4:1605–16. https://doi.org/10.1158/1535-7163.MCT-04-0311.
Ghosh S, Tilak TVSVGK, Somasundaram V, Deepti M. The domino effect-treatment of superior vena cava obstruction triggering tumor lysis syndrome: a case report. SciMedicine J. 2021;3:44–50. https://doi.org/10.28991/scimedj-2021-0301-6.
Agsalda-Garcia M, Shieh T, Souza R, Kamada N, Loi N, Oda R, et al. Raman-Enhanced Spectroscopy (RESpect) probe for childhood non-hodgkin lymphoma. SciMedicine J. 2020;2:1–7. https://doi.org/10.28991/scimedj-2020-0201-1.
Tyagi AK, Singh RP, Agarwal C, Chan DCF, Agarwal R. Silibinin strongly synergizes human prostate carcinoma DU145 Cells to doxorubicin-induced growth inhibition, G 2-M arrest, and apoptosis. 2002.
Todor IN, Lukyanova NY, Chekhun VF. The lipid content of cisplatin- and doxorubicin-resistant MCF-7 human breast cancer cells. Exp Oncol. 2012;34:97–100.
Schwarzenbach H, Gahan PB. Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients. Cancer Drug Resist. 2019. https://doi.org/10.20517/cdr.2019.010.
Cacan E. Histone deacetylase-1-mediated suppression of FAS in chemoresistant ovarian cancer cells. Anticancer Res. 2016;36:2819–26.
Elshafae SM, Kohart NA, Altstadt LA, Dirksen WP, Rosol TJ. The effect of a histone deacetylase inhibitor (AR-42) on canine prostate cancer growth and metastasis. Prostate. 2017;77:776–93. https://doi.org/10.1002/pros.23318.
Melnikov SV, Söll D, Steitz TA, Polikanov YS. Insights into RNA binding by the anticancer drug cisplatin from the crystal structure of cisplatin-modified ribosome. Nucleic Acids Res. 2016;44:4978–87. https://doi.org/10.1093/nar/gkw246.
Agudelo D, Bourassa P, Beauregard M, Bérubé G, Tajmir-Riahi HA. tRNA binding to antitumor drug doxorubicin and its analogue. PLoS One. 2013. https://doi.org/10.1371/journal.pone.0069248.
Wu X, Zhao W, Cui Q, Zhou Y. Computational screening of potential regulators for mRNA-protein expression level discrepancy. Biochem Biophys Res Commun. 2020;523:196–201. https://doi.org/10.1016/j.bbrc.2019.12.052.
We wish to thank Heike Thiemeyer and Jan Torben Schille for their valuable comments and suggestions. Sandra Goericke-Pesch is acknowledged for her valuable comments and for providing reagents and resources. This publication was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft) and University of Veterinary Medicine Hannover, Foundation within the funding program Open Access Publishing. We wish to thank the German Academic Scholarship Foundation (Studienstiftung des Deutschen Volkes) for supporting EMP with a scholarship.
This research received no external funding.
Ethics approval and consent to participate
In accordance with German national legislation, this study does not require ethical approval, as all tissue samples were collected as follows: Either 1. The dog was euthanized due to poor prognosis, or 2. The bladder cancer was surgically removed, or 3. From leftover material from a diagnostic fine needle aspiration biopsy.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Functional analysis of differentially expressed genes (DEGs) and categorization of retrieved enriched biological processes.
The ProGENI top 300 genes associated with doxorubicin and carboplatin resistance quantified by metabolic activity and cell count in the characterized cell lines.
Functional analysis of top 300 genes associated with chemoresistance.
Log2 read counts of therapeutically relevant RTK genes.
About this article
Cite this article
Packeiser, EM., Taher, L., Kong, W. et al. RNA-seq of nine canine prostate cancer cell lines reveals diverse therapeutic target signatures. Cancer Cell Int 22, 54 (2022). https://doi.org/10.1186/s12935-021-02422-9
- Prostate cancer
- Bladder cancer
- Cell line
- Gene expression
- In vitro model
- Targeted therapy